The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

被引:38
|
作者
Goette, Matthias [1 ,2 ,3 ]
机构
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada
[3] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada
基金
加拿大健康研究院;
关键词
HIV-1; REVERSE-TRANSCRIPTASE; CROSS-RESISTANCE; MUTATIONAL BIAS; NS5A INHIBITOR; VIRUS; PROTEASE; FIDELITY; REPLICATION; INFECTION; VARIANTS;
D O I
10.1016/j.coviro.2012.08.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The selection of resistance to antiviral drugs depends on multiple parameters, including the genetic barrier that is often broadly defined as the number of mutations required to overcome drug selective pressure. In this review, it is intended to assess the roles of genetic barrier and viral fitness at various stages of the selection process. Several examples in the fields of HIV and HCV drug resistance show that the two parameters are distinct and independent. An analogy to the concept of kinetic versus thermodynamic control of chemical reactions supports a more narrow definition of the genetic barrier as the kinetic obstacle for the generation of genetic changes required to overcome selective pressure.
引用
收藏
页码:644 / 650
页数:7
相关论文
共 50 条
  • [41] Modelling the development of anthelmintic resistance in cyathostomin parasites: The importance of genetic and fitness parameters
    Sauermann, Christian W.
    Nielsen, Martin K.
    Luo, Dongwen
    Leathwick, Dave M.
    VETERINARY PARASITOLOGY, 2019, 269 : 28 - 33
  • [42] Impact of HIV resistance mutations, drug resistance and viral fitness on antiviral activity of tenofovir/abacavir/lamivudine in the ESS30009 study
    Ross, LL
    Gerondelis, P
    Rouse, EG
    Lim, ML
    Liao, Q
    Wine, BC
    Griffith, SK
    St Clair, MH
    Shaefer, MS
    Rodriguez, AE
    Gallant, JE
    Lanier, ER
    ANTIVIRAL THERAPY, 2004, 9 (04) : U119 - U119
  • [43] HIV-1 genetic variation and drug resistance development
    Megens, Sarah
    Van Laethem, Kristel
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2013, 11 (11) : 1159 - 1178
  • [44] Does transcriptional heterogeneity facilitate the development of genetic drug resistance?
    Farquhar, Kevin S.
    Rasouli Koohi, Samira
    Charlebois, Daniel A.
    BIOESSAYS, 2021, 43 (08)
  • [45] Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
    Speliotes, Elizabeth K.
    George, Jacob
    JOURNAL OF HEPATOLOGY, 2022, 76 (03) : 498 - 500
  • [46] Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks
    Wagner, Bradley G.
    Garcia-Lerma, J. Gerardo
    Blower, Sally
    SCIENTIFIC REPORTS, 2012, 2
  • [47] Analysis of drug resistance to HIV-1 protease using fitness function in genetic algorithm
    A Harishchander
    S Senapati
    D Alex Anand
    BMC Infectious Diseases, 12 (Suppl 1)
  • [48] Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks
    Bradley G. Wagner
    J. Gerardo Garcia-Lerma
    Sally Blower
    Scientific Reports, 2
  • [49] Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance
    Altmann, Andre
    Beerenwinkel, Niko
    Sing, Tobias
    Savenkov, Igor
    Daeumer, Martin
    Kaiser, Rolf
    Rhee, Soo-Yon
    Fessel, W. Jeffrey
    Shafer, Robert W.
    Lengauer, Thomas
    ANTIVIRAL THERAPY, 2007, 12 (02) : 169 - 178
  • [50] Genetic barrier to antiretroviral drug-resistance Focus on raltegravir, the first integrase inhibitor
    Delaugerre, C.
    MEDECINE ET MALADIES INFECTIEUSES, 2010, 40 : S1 - S10